Mindera Health™ becomes a Medi-Cal™ Credentialled Provider
August 19, 2024 08:00 ET
|
Mindera Health
San Diego, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Mindera Health, developer of Mind.Px™, the first realization of precision medicine in psoriasis, has completed the credentialling process to become a...
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
August 13, 2024 16:05 ET
|
Alumis Inc.
– Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis – – Initiated Phase 1 clinical trial for A-005 in healthy participants – – Completed IPO...
Mindera Health Announces Appointment of Kamal Adawi as Chief Financial Officer
August 12, 2024 08:00 ET
|
Mindera Health
San Diego, CA, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Ron Rocca, President and CEO of Mindera Health, said, “We’re very pleased to add Kamal to the executive team. I am thrilled to work with Kamal again...
[Latest] Global Medical Aesthetics Market Size/Share Worth USD 36,168.8 Million by 2033 at a 8.4% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
August 06, 2024 03:30 ET
|
Custom Market Insights
Austin, TX, USA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Medical Aesthetics Market Size, Trends and Insights By Product Type (Aesthetic...
Mindera Health Secures $14 Million to Advance Commercialization of First and Only Psoriasis Precision Medicine Test
July 31, 2024 08:00 ET
|
Mindera Health
San Diego, CA, July 31, 2024 (GLOBE NEWSWIRE) -- Mindera Health Inc. announces the closing of a $14M convertible note financing, led by Mountain Group Partners and other existing investors in...
Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
July 29, 2024 08:00 ET
|
Alumis Inc.
Alumis announced that patient dosing has commenced in the ONWARD Phase 3 clinical program for ESK-001 for the treatment of psoriasis.
$6.97 Billion Photodynamic Therapy Market Outlook, 2024-2032, Featuring Detailed Analysis of Gladerma, Sun Pharmaceutical Industries, Biofrontera, Lumibird, Bausch Health Companies, and More
June 06, 2024 04:22 ET
|
Research and Markets
Dublin, June 06, 2024 (GLOBE NEWSWIRE) -- The "Photodynamic Therapy Market Report by Product Types, Application, End-user, Countries and Company Analysis 2024-2032" report has been added to ...
Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
June 05, 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced that five abstracts will be presented at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference in Chicago June 8-10.
Dermatology Collaboration and Licensing Deals Report, 2016 to 2024, Featuring 600+ Companies and 400+ Deals
May 02, 2024 07:33 ET
|
Research and Markets
Dublin, May 02, 2024 (GLOBE NEWSWIRE) -- The "Dermatology Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Dermatology Collaboration and...
ROSEN, A TOP RANKED LAW FIRM, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – VTYX
April 08, 2024 16:48 ET
|
The Rosen Law Firm PA
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ventyx Biosciences, Inc. (NASDAQ: VTYX): (i) pursuant...